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Emerging Options in Immune-Mediated Hearing Loss
Hitomi Sakano, MD, PhD ; Jeffrey P. Harris, MD, PhD
Objective: AIED (autoimmune inner ear disease) is an autoimmune process that leads to the dysfunction of the inner ear,
resulting in ﬂuctuating, audiovestibular symptoms. Although the pathogenesis is likely heterogeneous, immune processes
within the inner ear ultimately lead to histopathologic changes and sensorineural hearing loss. This review will discuss the lat-
est evidence on treatment options.
Methods: A literature search on articles pertaining to the treatment of autoimmune inner ear disease was performed on
PubMed.
Results: Corticosteroid treatment continues to remain as ﬁrst line therapy for AIED but long-term responsiveness is poor.
Cytotoxic chemotherapies can be effective alternatives for steroid nonresponsive patients, but signiﬁcant side effects may limit
their use. Intratympanic steroid injections are beneﬁcial and although there is not enough evidence currently to supplant oral
steroid trial they may be a useful adjunct if steroid toxicity is an issue. The efﬁcacy of biologic agents has been variable. Com-
pared to placebo, etanercept does not improve the hearing improvement already attained by steroids alone. However, open
pilot studies of other biologic agents show hearing improvements, improvements in tinnitus/aural fullness/vertigo, ability to
wean steroid dependency, or beneﬁts in steroid-resistant AIED.
Conclusion: There is currently not enough evidence that alternative treatments supersede the use of initial steroid treat-
ment. Biologic agents and intratympanic steroid injections are relatively well tolerated and should be considered as adjunctive
therapy. More studies on the efﬁcacy of various biologics and more studies on the treatment of steroid resistant disease espe-
cially after initial beneﬁt are still needed. For those who eventually lose their hearing, cochlear implantation remains as a via-
ble option.
Key Words: Autoimmune inner ear disease, AIED, Cogan’s syndrome, immune mediated hearing loss, biologics.
Level of Evidence: expert opinion.
INTRODUCTION
Autoimmune inner ear disease (AIED) typically pre-
sents with bilateral, ﬂuctuating audiovestibular symp-
toms, and can be associated with a variety of autoimmune
disorders. These include, but are not limited to, Vogt-
Koyanagi-Harada syndrome, Cogan’s syndrome, Susac’s
syndrome, systemic lupus erythematous, rheumatoid
arthritis, granulomatosis with polyangiitis (ie, Wegener’s
granulomatosis), Behçet’s disease, systemic sclerosis,
inﬂammatory bowel disease (eg, Crohn’s, ulcerative coli-
tis), relapsing polychondritis, and temporal arteritis.
AIED can also be suspected in patients without systemic
symptoms, based on laboratory markers of autoimmune or
autoinﬂammatory processes (eg, OTOblot, Buffalo, NY,
USA; erythrocyte sedimentation rate; C-reactive protein;
rheumatoid factor; anti-nuclear antibody; anti-double-
stranded DNA; cytoplasmic antineutrophil cytoplasmic
antibodies (c-ANCA); and Complement C3, C4, and C1q)
after ruling out infectious causes such as syphilis and
human immunodeﬁciency virus (HIV). These tests can
also aid in the classiﬁcation of AIED.1
Cogan’s syndrome was one of the earliest deﬁned
syndromes of hearing loss described in the 1950s. He
characterized several case series2–4 of nonsyphilitic pro-
gressive bilateral vestibuloauditory disorders associated
with keratitis and other systemic symptoms. McCabe,5
however, was the ﬁrst to link Cogan’s syndrome with an
autoimmune process and to recommend treatment with a
combination of cyclophosphamide and dexamethasone.
Since then, the responsiveness of the hearing loss to ste-
roids has been an important indicator for diagnosing
AIED; although, as we later discuss, not all AIED is ste-
roid responsive.
The incidence of AIED is estimated to be less than
5 in 100,0006 and represents less than 1% of all SNHL.
Although it can be unilateral, it often affects both ears.
Symptoms usually ﬂuctuate over the course of weeks to
months, distinguishing it from presbycusis which occurs
over the course of years. The clinical presentation of
AIED may overlap with that of Meniere’s disease and can
be difﬁcult to distinguish from it. Thus, the presence of
additional systemic autoimmune ﬁndings, diagnosis of
autoimmune disorder, or laboratory ﬁndings of autoim-
mune markers may aid in the diagnosis.
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PATHOGENESIS
The inner ear is not an immunologically privileged
site. Early electron microscopy studies by Rask-Anderson
and Stahle suggest that the endolymphatic sac may be
the site of immunological processing.7 Subsequent studies
by Mogi and by Harris have shown that peripheral immu-
nization of animals can lead to antibody concentration
within the inner ear.8–10 The presence of the endolym-
phatic sac is necessary for the immune response.11 The
pathway of entry into the inner ear is suspected to be via
the spiral modiolar vein12,13 with entry of inﬂammatory
cells into the scala tympani.14 The cells are thought to
then proliferate and release inﬂammatory mediators that
initiate a cascade of events leading to hearing loss.12,14–16
It is not known what triggers the autoimmune
response. There are some studies that suggest that auto-
antibodies are produced against inner ear protein through
molecular mimicry in response to viral or bacterial infec-
tion. For example, viral infection has been proposed to lead
to autoantibodies in Cogan’s syndrome which recognize
peptide sequences that are similar between REOVIRUS
III core protein lambda and autoantigens DEP-1/CD148
(found on endothelium) and Connexin 26 (found in the
inner ear).17 T-cells may also be involved in AIED. T-cells
recognizing cochlin, an abundant inner ear protein has
been found frequently in AIED patients.18
It is known that one-third of patients with suspected
AIED have circulating antibodies that recognize a 68kDa
inner ear protein by Western blot.19 Heat shock protein
70 (HSP70) has been proposed to be one protein that cor-
respond to this molecular weight.20 It is a ubiquitously
expressed housekeeping protein and, therefore, immune
response to this protein is thought to be a bystander
effect, not an actual cause for hearing loss. The identiﬁca-
tion of the 70kDa protein band on Western blot of inner
ear proteins using patient serum antibodies had been the
basis for the OTOblot test. Unfortunately, the commer-
cialized test now uses recombinant bovine HSP70, which
is less sensitive than the original test using inner ear pro-
tein extract. A recent study comparing AIED patients to
controls found that the rate of OTOblot positivity was no
different.21 These results suggest that the test in its cur-
rent form is not useful. Sera from patients with progres-
sive hearing loss also react to additional proteins from
inner ear (eg, myelin protein P0, 27-30kDa, 33-35kDa,
45kDa, 50kDa, 58kDa, 80kDa).22–25
HISTOPATHOLOGY
There are a number of histopathologic changes that
can occur in the inner ear as a result of AIED. Endolym-
phatic hydrops (excessive ﬂuid expansion in the scala
media) is a common ﬁnding in the temporal bones of AIED
patients.26 Consistent with this, abnormal ECoG (electroco-
chleography) test is observed in more than half of AIED
patients.27 Patients with Meniere’s symptoms also have a
higher rate of systemic autoimmune disease compared to
what is expected in normal population.28 In animal models,
antigen challenge either in the inner ear or with inner ear
antigens consistently results in endolymphatic hydrops.29–31
The autoimmune process can result in direct destruc-
tion of inner ear structures. In Wegener’s granulomatosis,
vasculitis is observed in the cochlea, vestibule, and facial
nerve.32 Basement membrane Immunoglobulin G deposi-
tion and loss of spiral ganglion neurons have been observed
in Sjögren’s.33 Atrophy of the stria vascularis and loss of
spiral ganglion cells are observed in systemic lupus
erythematous.34–36 These inﬂammatory processes result in
ﬁbrosis and osteoneogenesis37–39 and retrograde neuronal
degeneration.26
TREATMENT
The treatment of AIED mirrors the treatment for
systemic autoimmune disease. Corticosteroids are the pri-
mary therapy, followed by chemotherapy for steroid non-
responders.40,41 The results for biologics are promising,
but heterogeneous, and there is still insufﬁcient random-
ized control trial evidence for its use as a ﬁrst-line ther-
apy.42 We discuss the current evidence for the various
AIED treatments below.
Systemic Steroids
Not all the pathways by which glucocorticoids
decrease inﬂammation are elucidated. It is known that
glucocorticoid effects are mediated through transcrip-
tional regulation.43 A simpliﬁed model of how steroids
decrease inﬂammation is schematically shown in
Figure 1. In the “transactivation” model, glucocorticoids
Figure 1. Mechanism of steroids.
Glucocorticoid steroid crosses cellular membranes and binds the
GR (glucocorticoid receptor) which is a DNA binding protein.
Together they translocate to the nucleus and activate the expres-
sion of anti-inﬂammatory genes that contain GRE (glucocorticoid
response element) sequences. Glucocorticoids can also inhibit NF-
KB (nuclear factor kappa-light-chain-enhancer of activated B cells)
transcription factor and indirectly inhibit the expression of pro-
inﬂammatory genes such as cytokines.
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diffuse through cells and bind glucocorticoid receptors,
causing their translocation into the nucleus where they
increase the expression of genes containing glucocorticoid
response element (GRE) sequences. The result is an
increase of anti-inﬂammatory gene expression. In the
“transrepression” model, glucocorticoids inhibit transcrip-
tion factors, such as nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-KB), and indirectly sup-
press the expression of pro-inﬂammatory genes such as
cytokines (eg, tumor necrosis factor α [TNFα]).
Steroids are very effective immunosuppressants and
are effective in improving hearing loss in AIED but the
effects are not long lasting. Initial response rate is 50% to
70%.27,44–46 A typical regimen used by the senior author
is prednisone at 60 mg/day or (1 mg/kg) for at least one
month47 or until symptoms stabilize, followed by a taper.
Unfortunately, many people who beneﬁt from steroids
can develop resistance or relapse after taper, and only
14% remain steroid responsive by 34 months.27 Tinnitus
has been found to be a sensitive predictor of relapse.46 If
relapse occurs, steroids are resumed, however, prolonged
systemic steroid use is not ideal due to side effects.
Common side effects of long-term steroid use include
insulin resistance, obesity, osteoporosis, immunosuppres-
sion, gastric ulcers, adrenal suppression, and psychiatric
disturbances.47–49 When initiating short-term high-dose
steroid treatment, it is important to consider preexisting
conditions that may be worsened, including diabetes, high
blood pressure, and psychiatric illness such as anxiety
and depression, and discuss the risks and beneﬁts of
treatment with the patient. When continuing on long-
term steroids, it is important to engage the patient’s pri-
mary care physician for close monitoring of weight, com-
plete blood count, glucose, lipid, and osteoporosis and
cardiovascular risks,49 and for vigilance related to the
other potential adverse drug reactions discussed above.
Intratympanic Steroid Injection
In animal studies, higher level of steroids is mea-
sured in perilymph after intratympanic (IT) steroid injec-
tion compared to systemic administration.50 In
retrospective studies, IT steroid injection has been shown
to improve hearing in 54% (6 of 11) of oral steroid refrac-
tory patients51 and in 50% (15 of 30) of patients overall.46
There is currently no randomized control trial examining
the effect of IT versus oral steroids in AIED, thus, there
is not enough evidence to recommend that IT steroids
should be administered in lieu of oral route. However, it
is a relatively safe adjunctive or second line therapy.
Chemotherapy
Cyclophosphamide is an effective cytotoxic alkylat-
ing agent and immunosuppressant (see Table I). McCabe
used a combination of steroids and cyclophosphamide on
all of his patients and had on average 15 dB pure tone
improvement and 20% speech discrimination score
improvement.51 It cannot be determined how much the
effect was attributed to cyclophosphamide versus ste-
roids. Since then, there is very limited data aside from a
few case reports. In a more recent retrospective study the
results have not been as good: of 6 patients treated with
cyclophosphamide, only 2 had improved or stable hearing,
2 had no response, and 2 dropped out due to side
effects.27 Signiﬁcant side effects preclude its use, includ-
ing myelosuppression, nausea, alopecia, infertility,
increased risk for infection, and malignancy. Close moni-
toring with complete blood count, liver function test and
urinalysis is needed.
Methotrexate is an immunosuppressant that is better
tolerated than cyclophosphamide (see Table I for mecha-
nism of action). The drop-out rate due to toxicity is less
than 10%.27,52,53 Toxicity includes myelosuppression,
mucosal ulcerations, liver toxicity, renal failure, pneumoni-
tis, teratogenicity, and increased lymphoma risk. With the
exception of one retrospective study, which showed no
hearing improvement in 83% despite treatment with
methotrexate,27 many open-label studies had shown prom-
ising results. The drug improved hearing in 50% to 70% of
steroid responsive patients52–55 and improved vestibular
symptoms in 80% to 100%.54,55 However, a randomized
control trial of 67 steroid responsive AIED patients showed
that the addition of methotrexate at the end of steroid
taper was no more effective than placebo in maintaining
the hearing improvement achieved by steroids.48
There are alternative drugs such as azathioprine27,56,57
and mycophenolate,58 but they are less well studied.
Plasmapharesis
Plasmapharesis is typically reserved in severe cases
of autoimmune disorder that progress rapidly with vascu-
litis, leukopenia, thrombocytopenia or organ involvement
despite immunosuppression.59 It has been reported to
help stabilize hearing when it has been used.60,61
TABLE I.
Anti-inﬂammatory Mechanisms of Methotrexate and Cyclophosphamide
Methotrexate
Inhibition of purine biosynthesis! elevated extracellular adenosine levels! downregulation of T-cells and inﬂammation (this is thought to be the major
pathway)
Antagonism of folate ! inhibition of DNA synthesis! apoptosis and T-cell reduction (this is the main pathway for the chemotherapeutic effects but is not
thought to be the major pathway for reducing inﬂammation)
Cyclophosphamide
Metabolism by cytochrome-P450 into phosphoramide mustard! adds alkyl group to guanine base of DNA! inhibition of DNA replication! cell death,
affecting both resting and dividing lymphocytes.
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Biologic Agents
An exciting development in the last 10 to 15 years
has been the introduction of biologic agents for the treat-
ment of autoimmune disease. These are engineered anti-
bodies that target speciﬁc molecules of the immune
system. There are generally three types that are being
investigated in AIED (see Fig. 2 and Table II). One group
targets TNFα (eg, inﬂiximab [Remicade], adalimumab
[Humira], golimubab [Simponi], and etanercept [Enbrel].
Another targets B-cells (eg, rituximab [Rituxan]). And a
third targets IL-1beta (eg, anakinra [Kineret]). These bio-
logics can suppress the immune system and there is
increased risk for upper respiratory infections, neutrope-
nia, and infusion site reactions. However, a study review-
ing clinical trials of various biologics found that, although
newer TNFα inhibitors have higher side effect proﬁle,
overall, there was no signiﬁcant difference in the risk of
infection, infusion site reaction, malignancy, or mortality
between control and experimental groups.62 These drugs
are relatively well tolerated.
Figure 2. Mechanism of biologic agents.
Rituximab targets CD20 antigen on B-cell membranes, causing reduction of B-cells by apoptosis or by complement and antibody mediated
cytotoxicity. Etanercept, golimumab, adalimumab and inﬂiximab targets TNF (tumor necrosis factor) and prevents its effects through TNFR
(TNF receptor). Anakinra is a IL-1R (IL-1 receptor) agonist and competitively reduces the activity of both IL-1α and IL-1β.
TABLE II.
List of Biologics Used for AIED and Relevant Literature
Agent Structure/Target Reference Study Details
TNFα inhibitor
Inﬂiximab (Remicade) Human-mouse chimeric monoclonal antibody targets
soluble and membrane TNFα
Van Wijk et al., 2006 Prospective pilot study on transtympanic
inﬂiximab, n = 9.
Golimumab (Simponi) Human monoclonal antibody targets soluble and
membrane TNFα
Derebery et al., 2014 Open label study on transtympanic golimumab,
n = 7.
Adalimumab (Humira) Human monoclonal antibody targets soluble and
membrane TNFα
Matsuoka et Harris, 2013 Retrospective review, n = 10.
Etanercept (Enbrel) TNF receptor fused to human antibody targets
soluble and membrane TNFα
Rahman et al., 2001 Cites a meeting abstract reporting a pilot study,
n = 12.
Matteson et al., 2005 Open label pilot study, n = 23.
Cohen et al., 2005 Pilot placebo-controlled trial, n = 10 each arm.
B-cell inhibitor
Rituximab (Rituxan) Human-mouse chimeric monoclonal antibody
targeting CD20 on B-cell membranes
Cohen et al., 2011 Open label pilot study, n = 7.
Matsuoka et Harris 2013 Retrospective review, n = 5.
IL-1 inhibitor
Anakinra (Kineret) Recombinant form of IL-I receptor antagonist (IL-1Ra)
which blocks IL-1 receptor and reduces the
activities of both IL-1α and IL-1β
Vambutas et al., 2014 Phase I/II open label, single-arm clinical trial,
n = 10.
Note: Case reports not included. TNF (tumor necrosis factor); IL-1 (interleukin-1); CD20 (cluster differentiation 20).
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TNFα Antagonists
TNFα is a pro-inﬂammatory cytokine and is an indi-
cator of steroid responsiveness in AIED.63 Using an
established mouse model of AIED immunized with KLH
antigen, etanercept has been found to decrease the num-
ber of inﬁltrating cells in the cochlea in response to
TNFα.64 Several open-pilot studies show variable hearing
results with etanercept in steroid responsive patients. In
one reported study of 12 patients, 58% had hearing
improvement.65 In another with 23 patients, 30% had
improved hearing and 58% had stable hearing.66 How-
ever, a pilot placebo-controlled study of steroid responsive
AIED patients found no difference in the hearing
improvement between etanercept and placebo.67
Yet another TNF αantagonist, inﬂiximab, delivered
by local intratympanic (IT) infusion once weekly for
4 weeks has been found to stabilize hearing and allow
4 of 5 steroid-dependent patients to wean off steroids, or
improve hearing loss in 3 of 4 steroid-responsive patients
who relapsed after steroid cessation.68 Another study of
10 steroid-dependent AIED patients who underwent IT
golimumab therapy found that 6 had stable thresholds in
the injected ear and 7 patients were able to wean off
steroids.69
TNFα antagonist is not useful in steroid refractory
AIED. In a study of 8 patients who did not respond to ste-
roids, systemic treatment with inﬂiximab was not helpful
in hearing improvement.70
IL-1β Antagonists
One of the challenges of AIED is the treatment of
steroid nonresponders. While steroids are known to sup-
press IL-1β through indirect pathways, one study sug-
gests that the IL-1β pathway is abnormally upregulated
in steroid resistant patients.71 They also showed that IL-
1β antagonist anakinra can decrease IL-1β in otherwise
steroid-nonresponsive monocytes. This is promising for
the potential use of anakinra for steroid-nonresponsive
patients. A phase I/II study showed that in an intention
to treat analysis, 58% response rate with anakinra injec-
tion in steroid-nonresponsive AIED.72 The drug was well
tolerated, aside from a risk of injection site reaction rate
of 70%.
B-Cell Antagonists
Rituximab is a B-cell inhibitor targeting CD20. A
small open pilot study of 7 patients tolerated rituximab
without signiﬁcant side effects and 5 were able to main-
tain the post-steroid hearing improvement.73 There is one
case report of a Cogan’s syndrome patient who did not
respond to prednisone, methotrexate, cyclophosphamide,
cyclosporine, and adalimumab (TNFα inhibitor), but did
have hearing improvement after rituximab.74 In a retro-
spective study, hearing improved in only 2 of 5 treated
with rituximab, but all patients improved tinnitus, aural
fullness, and vertigo.46
Cochlear Implantation
For those patients whose hearing could not be sal-
vaged, cochlear implantation is an excellent rehabilitative
option.75–77 Although neo-ossiﬁcation (which required
drill out) and intraluminal ﬁbrosis was seen in 50% of
implanted ears, all ears were implanted and the outcomes
on word and sentence scores were not signiﬁcantly differ-
ent between AIED and postlingually deaf control
patients.75 This option is especially important for those
patients unable to tolerate the side effects of immunomo-
dulating drugs and go on to develop bilateral deafness.
DISCUSSION
Assessment of AIED treatment is difﬁcult because of
the scarcity of patients to perform large clinical trials.
Currently, there is no randomized control study compar-
ing steroids to alternative medications. Therefore, at this
time, the use of alternative drugs cannot be recommended
as a substitute for initial steroid trial.
Currently, steroids are a consistently effective for
AIED in more than half of patients. There are two prob-
lems. One is that the effects are not long lasting. In
patients who relapse, the current recommendation is to
resume steroids but this is not a great long-term solution
given its side effects. Unfortunately, placebo controlled
studies suggest that use of alternative medications such as
methotrexate and etanercept do not improve upon the
hearing results already attained by steroids.48,67 These
results could be explained because the effects of medica-
tions could have been dampened by the steroid effects.
Also, different biologics may have variable effects. Open
pilot study on rituximab suggests that it may help main-
tain hearing achieved by steroids.73 Studies suggest that
IT injection of inﬂiximab and golimumab68,69 can help
patients wean off steroid dependency. In our experience
(unpublished), we have found rituximab and adalimumab
therapy can be helpful in weaning steroids either
completely or to low tolerable doses of 10 mg/day. It is
worth considering the use of biologics as a maintenance
medication in an attempt to wean steroid dependence.
The second problem is the dilemma of treating
patients who are refractory to steroids. Chemotherapy is
the usual next step, however, signiﬁcant side effects are the
primary reason many patients and providers have shied
away from cyclophosphamide. Methotrexate appears to be
better tolerated. We do not know how effective they are in
steroid nonresponders because many large-scale studies
have selected for steroid-responsive patients. IT steroid
injection has been shown to be helpful in half of steroid non-
responders55 and should be recommended. Can we also con-
sider biologics? Studies suggest that the TNFα antagonists
likely affect steroid pathways, and may explain why these
drugs are not helpful in steroid nonresponders.70 There are
some suggestions that other cellular pathways, such as IL-
1β, may be abnormally regulated in steroid nonresponders
and can serve as alternative therapeutic targets.71 IL-1β
phase I/II study showed promising results using anakinra
biologic,72 but more studies are needed before strong recom-
mendations can be made.
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Although the beneﬁts of chemotherapy and biologics
on hearing improvement have been variable, what is
underappreciated is the apparent beneﬁt of biologics on
other aural symptoms of fullness, vertigo, and tinnitus.
In a retrospective study, less than half of patients treated
with adalimumab or rituximab had hearing improvement
but >80% had improved tinnitus, aural fullness, and ver-
tigo.46 Similarly with methotrexate, the improvement
rate for vestibular symptoms can range from 80% to
100%.54,55 Thus, one should not eliminate the use of non-
steroid treatment based on lack of hearing improvement
alone.
CONCLUSION
Whatever the initial insult or trigger may be, the
autoimmune process leads to destructive changes in the
inner ear and ultimately neural degeneration and hear-
ing loss. Thus, the most effective treatments have been
focused on modulating the immune system. Corticoste-
roids continue to remain the most effective and primary
recommended treatment. Currently, there is not enough
evidence to recommend the use of alternative medication
to replace an initial steroid trial. Intratympanic steroid
injection and chemotherapies remain as alternative
options that can be considered, especially in steroid non-
responders, but with the latter pose signiﬁcant side
effects that may limit their use. Promising advancements
have been made in biologics in the treatment of autoim-
mune disorders. The effects on hearing improvement
have been variable with various biologics, suggesting that
the effect of one biologic is not generalizable to others.
Aside from the effects on hearing, there is evidence of the
usefulness of biologics in weaning steroid dependency,
treatment of steroid nonresponders, and the potential
beneﬁts in vertigo, aural fullness, and tinnitus. More
studies are needed on the effectiveness of each biologic
and more studies are needed on the treatment of steroid
nonresponsive patients. Ultimately, if hearing is lost,
cochlear implantation is a very effective treatment option
for these patients.
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